Tag: Advanced Accelerator Applications

Gallium 68 PET/CT Scanning for Neuroendocrine Tumors — Information and Locations

April 6, 2017

The US Food and Drug Administration’s (FDA) June 1, 2016 approval of the Gallium-68 PET/CT DOTATATE scan using NETSPOT® heralded a new age of nuclear imaging for neuroendocrine tumors in the United States.

PLEASE SCROLL DOWN FOR A STATE-BY STATE LISTREAD MORE

Fighting NET Cancer with Grace and Gratitude

November 9, 2016

The Carcinoid Cancer Foundation is very excited to share what we have planned around this year’s Worldwide NET Cancer Awareness Day, November 10, and hope you will help us spread the word about NET cancer to support and inspire one another, and those …

READ MORE

October Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community

September 1, 2016

Join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for Luncheon with the Experts in New York City on Sunday, October 16, 2016.  This special program was initiated and is sponsored by the Big Apple NETs support group,…

READ MORE

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

May 3, 2016

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017.  Additionally, an

READ MORE

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, March 2016

March 23, 2016

Breaking News from Advanced Accelerator Applications (AAA) about PRRT Treatment— Advanced Accelerator Applications announced on March 23 that the company has initiated an expanded access program (EAP) in the United States for the investigational…

READ MORE

Neuroendocrine Tumors to Be Focus of Presentations and Posters at ASCO Gastrointestinal Cancers Symposium

January 14, 2016

Presentations on recent advances in the treatment of neuroendocrine tumors (NETs) and new findings from the NETTER-1 clinical study on PRRT with Lutathera along with posters on a wide variety of subjects about NETs will be part of the program during the…

READ MORE

10 Highlights of the Year 2015 for the Carcinoid and Neuroendocrine Tumor Community

January 5, 2016

As we begin a new year, the Carcinoid Cancer Foundation looks back on the highlights of 2015 and to a future that we hope will bring greater awareness of carcinoid and neuroendocrine cancers, earlier diagnosis for patients, new treatment options, and …

READ MORE
Ebrahim S. Delpassand, MD

First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate

November 20, 2012

Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …

READ MORE